NCT02333760View on ClinicalTrials.gov

Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2032

Study Completion Date

October 31, 2032

Conditions
Wiskott-Aldrich Syndrome
Interventions
GENETIC

Autologous CD34+ cells transduced with WASP lentiviral vector

Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene

Trial Locations (2)

75743

Hopital Necker - Enfants Malades, Paris

WC1N 1EH

UCL Institute of Child Health, London

Sponsors

Lead Sponsor

Genethon
All Listed Sponsors
lead

Genethon

OTHER

NCT02333760 - Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome | Biotech Hunter | Biotech Hunter